Home›Research›Compare›Angiotensin (1-7) vs ARA-290
Peptide ComparisonAngiotensin (1-7) vs ARA-290
Both are Longevity & Cellular peptides.
Angiotensin (1-7)
Ang-(1-7)
Half-life: ~9–10 sec (rat)
No providers listed yet
ARA-290
Cibinetide
Half-life: ~2 min (IV); ~10–20 min (SC)
16 providers listed
Angiotensin (1-7) has a longer half-life than ARA-290, so it generally needs less frequent dosing.
Angiotensin (1-7)
Evidence
Half-life
~9–10 sec (rat)
ARA-290
Evidence
Half-life
~2 min (IV); ~10–20 min (SC)
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Angiotensin (1-7) |
| Less frequent dosing (longer half-life) | Angiotensin (1-7) |
| More provider options (0 vs 16) | ARA-290 |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Angiotensin (1-7)
ARA-290
Angiotensin (1-7)
The Effect of Angiotensin (1-7) on Serum Metabolomics in Obese Type 2 Diabetic Mice.
Perioperative Angiotensin-(1-7) for Postoperative Cognitive Vulnerability Following Coronary Artery Bypass Su…
Severe Acute Hypertension Causes Hemolysis With Release of PEP and ACE Inhibitor.
Neuroprotective effects of telmisartan in a harmaline-induced model of essential tremor: modulation of the re…
+11 more
ARA-290
Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice.
Cibinetide (ARA 290) reduces small nerve fiber pathology in sarcoidosis patients
ARA 290, a non-hematopoietic erythropoietin analogue, improves metabolic control and neuropathic symptoms in…
About Angiotensin (1-7)
Binds Mas receptor (MasR), activating nitric oxide synthase and reducing oxidative stress. Opposes TGF-β and angiotensin II signaling to reduce fibrosis. Enhances insulin sensitivity and provides cardiovascular protection.
About ARA-290
Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Angiotensin (1-7)
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
ARA-290
No established clinical contraindications
Angiotensin (1-7)
Not enough vendor pricing yet.
ARA-290
Where to source these peptides
Angiotensin (1-7)
Browse directory →
Providers offeringARA-290
16 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Longevity & Cellular Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 27, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Angiotensin (1-7) vs ARA-290 — Per-mg Price Comparison. Retrieved July 29, 2026, from https://peptidebase.io/peptides/compare/angiotensin-1-7/ara-290